Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Licenses Rights to Pancreatic Cancer Gene Patents

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market Thursday that it has licensed exclusive rights from Johns Hopkins University to patents covering a gene related to pancreatic cancer.

The Salt Lake City-based molecular diagnostics firm said the worldwide, exclusive license covers rights to patents covering mutations in the PALB2 gene, which have been found to increase an individual's risk for developing pancreatic cancer. The company hopes to launch a new predictive test next year containing markers for hereditary pancreatic cancer.

Earlier this year, researchers from the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins University published a paper in the journal Science, in which they presented the PALB2 gene as a susceptibility gene for familial pancreatic cancer. Myriad noted that in addition to this gene, the BRCA2 and p16 genes also have been discovered as playing a role in familial pancreatic cancer. The firm holds exclusive rights under 10 issued US patents to those other two genes.

According to Myriad, an individual that has a mutation in one or more of those three genes, their risk of developing pancreatic cancer by age 70 may be as high as 10 to 20 times greater than that of the general population.

Terms of the license were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.